Myeloma Patients in Phase 1 Trial Show High Response Rates with REGN5458 Treatment
Treatment with Regeneron Pharmaceuticals‘ investigational therapy REGN5458 was well tolerated and significantly lowered the tumor burden in more than…
News
PNK-007 Treatment After Stem Cell Transplant Leads to Good Response Rates in Multiple Myeloma Patients, Early Trial Data Show
A single infusion of Celularity‘s PNK-007 — an investigational cell therapy derived from placental stem cells — is safe and leads to good response…
Analysis Group Announces Collaboration to Improve Blood Disease Research and Treatment in China
Analysis Group is collaborating with China’s Institute of Hematology & Blood Diseases Hospital (IHBDH) to develop the country’s first blood disorders research platform…
Top 10 Multiple Myeloma Stories of 2019
Myeloma Research News brought you daily coverage of important findings, treatment developments, clinical trials, and other events related to multiple myeloma…
Switching Chemo Types in Initial Combo May Help Myeloma Patients with Poor Response, Study Says
For people with multiple myeloma who don’t respond well to an initial type of therapy, quickly switching to another type may improve clinical outcomes,…
CHMP Recommends EU Approval of Darzalex Combo as First-line Treatment for Transplant-eligible Myeloma Patients
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Darzalex (daratumumab), in combination with standard pre-transplant therapy, for the treatment of…
MGUS Patients Have More Frequent Hospital Visits Prior to Diagnosis than Healthy Controls, Research Shows
People with monoclonal gammopathy of undetermined significance (MGUS), a rarely diagnosed condition that can progress to myeloma, go to the hospital twice as often…
Advanced Multiple Myeloma Patients Responding to Janssen’s CAR T-cell Therapy, Trial Data Show
Janssen’s investigational CAR T-cell therapy for multiple myeloma, called JNJ-4528 (JNJ-68284528), safely led to early and deep responses in all patients with relapsed or…
Kyprolis Combo Followed by Stem Cell Transplant is Effective for Most Smoldering Multiple Myeloma, Data Show
A combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone, given before and immediately after a stem cell transplant, is effective…
Ninlaro Triple Combo Delays Progression of High-Risk Smoldering Multiple Myeloma, Trial Suggests
Early treatment with a triple combination therapy containing Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone in patients with high-risk smoldering multiple…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML